COMPASS Pathways Announces Positive Results From Their Phase 2 Trial assessing Synthetic Psilocybin COMP360 Alongside SSRIs for Treatment-Resistant Depression

LONDON, July 17, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company focused on mental health, has announced positive data from an open-label phase 2 clinical trial of COMP360 psilocybin in combination with selective serotonin reuptake inhibitors (SSRIs) for treatment-resistant depression in the peer reviewed Nature journal, Neuropsychopharmacology. The trial involved 19 participants, and the results showed that SSRIs did not interfere with the potential therapeutic effect of COMP360.

  • Response (a greater than 50% reduction from baseline in MADRS total score[1]) and remission (MADRS total score of 10 or less) was seen in 42% of participants at week three.
  • The efficacy findings were similar to those from COMPASS’s Phase 2b study of 25mg of COMP360 psilocybin in treatment-resistant depression, where patients were withdrawn from their antidepressants prior to receiving COMP360 (42% response and remission rates at week three versus 37% and 29%, respectively).
  • COMP360 psilocybin treatment was generally well tolerated. The most common treatment emergent adverse event was headache. No serious adverse events were reported.

Dr. Guy Goodwin, Chief Medical Officer at COMPASS Pathways, said, “It has long been thought that SSRIs could interfere with the potential therapeutic effect of psilocybin. This data is exciting because it provides a preliminary signal that this is not the case, and that patients could remain on their SSRI antidepressant medication and experience the same effect from COMP360 psilocybin treatment as people who are not on SSRIs. This could have important clinical implications for patient choice, if COMP360 psilocybin treatment receives regulatory approval for treatment-resistant depression. Withdrawing from antidepressants can be unwelcome for some patients, so the possibility of having the choice to remain on their antidepressant could eventually make COMP360 psilocybin treatment more accessible.”

The data indicates that the potential therapeutic effect of COMP360 is not hindered by concurrent SSRI use, which could have significant clinical implications for patient choice and accessibility. COMP360 is COMPASS’s proprietary formulation of synthetic psilocybin, administered alongside psychological support. The company is currently conducting a phase 3 clinical program for COMP360 psilocybin treatment in treatment-resistant depression, the largest study of its kind.

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin treatment, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

We have commenced a phase 3 clinical program of COMP360 psilocybin treatment in TRD, the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single 25mg dose of COMP360 psilocybin with psychological support. We are also conducting phase 2 clinical studies of COMP360 psilocybin treatment for post-traumatic stress disorder (PTSD) and anorexia nervosa.

COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the United States. Our vision is a world of mental wellbeing.

FDA Approval Greenlights MDMA Trial for Schizophrenia
magic mushrooms in the background and news title

FDA Approval Greenlights MDMA Trial for Schizophrenia

here is what's next

Weekly Psychedelic News – Week 29, 2023

Weekly Psychedelic News – Week 29, 2023

Stay up-to-date with the latest in the world of psychedelics with our weekly

You May Also Like

Join Psilolab Newsletter!

Welcome to the Psilolab newsletter, where we delve into the fascinating world of psychedelics and their impact on mental health. In this space, we explore the latest research and breakthroughs in the field of psychedelics and how they are being used to treat various mental health conditions such as depression, anxiety, PTSD, and addiction.

Join us on this journey as we explore the mind, reality, and the transformative power of psychedelics.